This publication has been discontinued on September 5, 2012.
Introduction
Abstract
Greystone Research Associates is pleased to announce the publication of a new
market study. Systemic Nasal Sprays: Products, Players, Markets and Forecasts
is a comprehensive evaluation and analysis of the technology, products and
participants providing the driving force behind this evolving segment of the
healthcare sector.
The study is designed to provide drug company decision makers, drug
developers, device packaging designers, healthcare marketers, and supply chain
participants with a detailed understanding of the products, markets and
commercial opportunities for systemic drugs that are administered
intranasally. Provider organization business managers, healthcare
administrators and investors will also benefit from this study.
The Evolving Landscape
Drug developers and researchers are discovering that the accessibility and
vascular structure of the nose make it an attractive route for delivering both
small molecule drugs and biologics, systemically as well as across the
blood-brain barrier to the CNS.
Nasal delivery offers the potential for faster onset of action and less
frequent dosing relative to oral drugs. As aging population demographics and
managed care initiatives drive growth in home health care and
self-administration of drug therapies for chronic conditions such as diabetes,
arthritis, and hormone replacement therapy, drug developers are showing
increased interest in routes of administration that are patientfriendly and
cost-effective. Intranasal administration is well positioned to take advantage
of these trends and evolve into a significant role in the future of
pharmaceutical development and commercialization. Intranasal delivery will
grow at the expense of the predominant drug delivery methods (oral and
parenteral), which cannot be readily optimized for the delivery and dosing of
a significant portion of biologically derived drug substances.
Highlights
Analyzes and evaluates nasal sprays for systemic drug deliveryand
development-stage candidates and assesses risks and market potential
Analyzes nasal spray product strategies, technologies and patch
development issues
Provides assessments of intranasal systemic drug products, key design
factors and strategic device factors
Provides market data and forecasts to 2016
Profiles market sector participants, their product development activities
and business strategies
Methodology
Research methodology is based on primary research in the form of in-depth
interviews with key market participants, technology developers, distributors,
industry experts, and market influencers, a list that includes regulatory
officials, industry trade groups, and materials standards organizations.
Primary data is evaluated and normalized against secondary sources including
trade journal articles, technical literature, industry publications, company
data sheets and published information, and statistical data from government
agencies and trade associations.
Forecasts and projections of market demand and future market activity are
derived using standard modeling and statistical techniques.
About Greystone Associates
Greystone Associates is a medical technology consulting firm focused on the
areas of medical market strategy, product commercialization, venture
development, and market research. We assist medical and healthcare market
participants in achieving their business objectives through the creation of
detailed development strategies, product commercialization programs, and
comprehensive market and technology research and analysis.
Our market research publications are designed, researched and written to
provide timely and insightful information and data on focused market segments,
with the aim of providing market participants with the essential knowledge to
refine and execute their marketing plans and financial targets.
Table of Contents
Table of Contents
Executive Summary
Systemic Nasal Delivery Market Dynamics
The Trend toward Self-Administration
Demographic Shifts
Managed Care Initiatives
Growth in Home Healthcare
Technology Market Drivers
Competitive Landscape
Nasal Delivery Design Factors
Absorption
Bioavailability
Device Design Parameters
Nasal Delivery Pharmacokinetics
Nasal Device Characteristics
Market Factors
Regional Regulations
Clinical Trials
Indications and Off-Label Prescribing
Managed Care and Payor Initiatives
Rx-to-OTC Switching
Product Assessments and Market Prospects
Approved Drug Products
Butorphanol
Desmopressin
FluMist
Fortical
Imitrex
Instanyl
Lazanda
Miacalcin
Migranal
Nicotrol
Synarel
Zomig
Development-Stage Products
Apomorphine
Cytokines
Emitasol
Exenatide
Insulin
Ketamine
Leuprolide
Morphine
Parathyroid
Peptides
Triazolam
Nasal Delivery Indications and Markets
Addiction
Anti-Emetics
Autism
Diabetes
Endocrine Therapy
Immune Therapeutics
Migraine
Metabolic Disorders
Osteoporosis
Pain Management
Parkinson's Disease
Reproductive Medicine
Sleep Disorders
Urology
Market Forecasts
Forecast Methodology
Forecasts by Region
Market Share Data
Company Profiles
Press Release
Greystone Research Publishes New Study on Systemic Nasal Sprays
May 30th, 2012
Global Information Inc. would like to present a new market research report, "Systemic Nasal Sprays: Products, Players, Markets and Forecasts" by Greystone Research Associates.
Systemic Nasal Sprays: Products, Players, Markets and Forecasts is a comprehensive evaluation and analysis of the technology, products and participants providing the driving force behind this evolving segment of the healthcare sector.
As aging population demographics and managed care initiatives drive growth in home health care and self-administration of drug therapies for chronic conditions such as diabetes, arthritis, and hormone replacement therapy, drug developers are showing increased interest in routes of administration that are patient-friendly and cost-effective.
Drug developers and researchers are discovering that the accessibility and vascular structure of the nose make it an attractive route for delivering both small molecule drugs and biologics, systemically as well as across the blood-brain barrier to the CNS. Nasal delivery offers the potential for faster onset of action and less frequent dosing relative to oral drugs.
Intranasal administration is well positioned to evolve into a significant role in the future of pharmaceutical development and commercialization. Intranasal delivery will grow at the expense of the predominant drug delivery methods (oral and parenteral), which cannot be readily optimized for the delivery and dosing of a significant portion of biologically derived drug substances.
